Needham & Company LLC reaffirmed their positive rating on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Wednesday, The Fly reports. The brokerage currently has a $74.00 price target on the stock.
Other analysts have also issued reports about the stock. ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Oppenheimer set a $13.00 price objective on shares of Alpine Immune Sciences and gave the stock a buy rating in a research report on Tuesday, March 19th. BidaskClub lowered shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, June 26th. Mizuho reissued a buy rating and issued a $77.00 price objective on shares of Aerie Pharmaceuticals in a research report on Sunday, April 21st. Finally, Piper Jaffray Companies set a $76.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a research report on Friday, July 5th. Three analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $71.25.
Aerie Pharmaceuticals stock traded down $0.82 during midday trading on Wednesday, reaching $25.05. The stock had a trading volume of 614,168 shares, compared to its average volume of 640,661. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.27 and a current ratio of 3.47. Aerie Pharmaceuticals has a 52-week low of $24.78 and a 52-week high of $74.75. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.39 and a beta of 0.54. The stock has a fifty day simple moving average of $32.52.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.13. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%. The company had revenue of $10.85 million for the quarter, compared to analyst estimates of $12.66 million. On average, equities analysts forecast that Aerie Pharmaceuticals will post -2.6 EPS for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Truvestments Capital LLC bought a new position in shares of Aerie Pharmaceuticals during the first quarter valued at approximately $33,000. Quantamental Technologies LLC acquired a new stake in Aerie Pharmaceuticals in the first quarter valued at approximately $41,000. Oppenheimer Asset Management Inc. acquired a new stake in Aerie Pharmaceuticals in the first quarter valued at approximately $47,000. Meeder Asset Management Inc. boosted its stake in Aerie Pharmaceuticals by 134.0% in the first quarter. Meeder Asset Management Inc. now owns 1,060 shares of the company’s stock valued at $50,000 after acquiring an additional 607 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in Aerie Pharmaceuticals in the fourth quarter valued at approximately $105,000.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Recommended Story: Conference Calls and Individual Investors
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.